Lawrence R Dick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5688392/publications.pdf

Version: 2024-02-01

471509 794594 4,387 19 17 19 citations h-index g-index papers 19 19 19 8473 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy. Science, 2022, 376, 1074-1079.	12.6	25
2	Design of proteasome inhibitors with oral efficacy in vivo against <i>Plasmodium falciparum</i> and selectivity over the human proteasome. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	19
3	The structure of the PA28–20S proteasome complex from Plasmodium falciparum and implications for proteostasis. Nature Microbiology, 2019, 4, 1990-2000.	13.3	31
4	The proteasome as a target for protozoan parasites. Expert Opinion on Therapeutic Targets, 2019, 23, 903-914.	3.4	32
5	A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nature Medicine, 2018, 24, 186-193.	30.7	258
6	Target Validation and Identification of Novel Boronate Inhibitors of the <i>Plasmodium falciparum</i> Proteasome. Journal of Medicinal Chemistry, 2018, 61, 10053-10066.	6.4	54
7	Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nature Communications, 2018, 9, 3801.	12.8	193
8	Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. Nature Chemical Biology, 2017, 13, 1164-1171.	8.0	163
9	Mechanistic Study of Uba5 Enzyme and the Ufm1 Conjugation Pathway. Journal of Biological Chemistry, 2014, 289, 22648-22658.	3.4	32
10	Absolute Quantification of E1, Ubiquitin-Like Proteins and Nedd8–MLN4924 Adduct by Mass Spectrometry. Cell Biochemistry and Biophysics, 2013, 67, 139-147.	1.8	13
11	Mechanistic Studies on Activation of Ubiquitin and Di-ubiquitin-like Protein, FAT10, by Ubiquitin-like Modifier Activating Enzyme 6, Uba6. Journal of Biological Chemistry, 2012, 287, 15512-15522.	3.4	38
12	Treatment-Emergent Mutations in NAE \hat{I}^2 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924. Cancer Cell, 2012, 21, 388-401.	16.8	98
13	Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets. Nature Reviews Drug Discovery, 2011, 10, 29-46.	46.4	456
14	Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues. Journal of Biological Chemistry, 2011, 286, 40867-40877.	3.4	78
15	Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S \hat{l}^2 5-subunit. Biochemical Journal, 2010, 430, 461-476.	3.7	148
16	Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ. Molecular Cell, 2010, 37, 102-111.	9.7	396
17	An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature, 2009, 458, 732-736.	27.8	1,626
18	Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Molecular Cancer Therapeutics, 2006, 5, 3052-3061.	4.1	68

#	Article	IF	CITATIONS
19	Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 333-338.	2.2	659